Vigabatrin for infantile spasms

Pharmacotherapy

Volumn 31, Issue 3, 2011, Pages 298-311

  Pesaturo, Kimberly A ^a   Spooner, Linda M ^a   Belliveau, Paul ^a  

^a MASSACHUSETTS COLLEGE OF PHARMACY AND HEALTH SCIENCES   (United States)

Author keywords

aminobutyric acid; ACTH; Adrenocorticotropic hormone; GABA; Infantile spasms; Vigabatrin; West syndrome

Indexed keywords

4 AMINOBUTYRIC ACID; CORTICOTROPIN; HYDROCORTISONE; PLACEBO; PREDNISOLONE; TETRACOSACTIDE; VIGABATRIN;

AREA UNDER THE CURVE; BEHAVIOR DISORDER; CONFUSION; DOSE RESPONSE; DROWSINESS; DRUG ABSORPTION; DRUG ACTIVITY; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG MEGADOSE; DRUG STRUCTURE; DRUG WITHDRAWAL; ENANTIOMER; EXCITABILITY; GASTROINTESTINAL DISEASE; HUMAN; HYPERKINESIA; INFANTILE SPASM; INFECTION; INSOMNIA; INTRAPERITONEAL DRUG ADMINISTRATION; KIDNEY CLEARANCE; LOW DRUG DOSE; MUSCLE HYPERTONIA; MUSCLE HYPOTONIA; NONHUMAN; REVIEW; SEDATION; SIDE EFFECT; SINGLE DRUG DOSE; SLEEP DISORDER; TEMPORAL LOBE EPILEPSY; TIME TO MAXIMUM PLASMA CONCENTRATION; VISUAL FIELD DEFECT;

ADRENOCORTICOTROPIC HORMONE; ANTICONVULSANTS; CHILD, PRESCHOOL; CLINICAL TRIALS AS TOPIC; ELECTROENCEPHALOGRAPHY; EPILEPSY; HUMANS; INFANT; SPASMS, INFANTILE; TREATMENT OUTCOME; TUBEROUS SCLEROSIS; VIGABATRIN;

EID: 79952434372     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.31.3.298     Document Type: Review

References (85)

1. Mikati MA, Lepejian GA, Holmes GL. Medical treatment of patients with infantile spasms. Clin Neuropharmacol 2002;25:61-70. (Pubitemid 34411822)
2. Lux AL, Osborne JP. A proposal for case definitions and outcome measures in studies of infantile spasms and West syndrome: consensus statement of the Delphi Group. Epilepsia 2004;45:1416-28. (Pubitemid 39470046)
3. Malphrus AD, Wilfong AA. Use of the new antiepileptic drugs in pediatric epilepsies. Curr Treat Options Neurol 2007;9:256-67. (Pubitemid 47064609)
4. Wheless JW, Clarke DF, Carpenter D. Treatment of pediatric epilepsy: expert opinion, 2005. J Child Neurol 2005;20(suppl 1):S1-56.
5. Wilton LV, Stephens MDB, Mann RD. Interim report on the incidence of visual field defects in patients on long-term vigabatrin therapy. Pharmacoepidemiol Drug Saf 1999;8:S9-14.
6. U.S. Food and Drug Administration. Drugs @ FDA. FDAapproved drug products. Available from www.accessdata.fda.gov/scripts/cder/drugsatfda/index. cfm. Accessed April 30, 2010.
7. Lippert B, Metcalf BW, Jung MJ, Casara P. 4-Amino-hex-5-enoic acid, a selective catalytic inhibitor of 4-aminobutyric-acid aminotransferase in mammalian brain. Eur J Biochem 1977;74:441-5. (Pubitemid 8080063)
8. Lundbeck Inc. Sabril (vigabatrin oral solution) package insert. Deerfield, IL; 2009.
9. Larsson OM, Gram L, Schousboe I, Schousboe A. Differential effect of γ-vinyl GABA and valproate on GABA-transaminase from cultured neurons and astrocytes. Neuropharmacology 1986;25:617-25. (Pubitemid 16056526)
10. Meldrum BS, Murugaiah K. Anticonvulsant action in mice with sound-induced seizures of the optical isomers of γ-vinyl GABA. Eur J Pharmacol 1983;89:149-52. (Pubitemid 13133382)
11. 14C]vigabatrin in healthy male volunteers. Drug Metab Dispos 1993;21:480-4.
12. Haegele KD, Huebert ND, Ebel M, Tell GP, Schechter PJ. Pharmacokinetics of vigabatrin: implications of creatinine clearance. Clin Pharmacol Ther 1988;44:558-65. (Pubitemid 19002870)
13. Saletu B, Grunberger J, Linzmayer L, Schwartz JJ, Haegele KD, Schechter PJ. Psychophysiological and psychometric studies after manipulating the GABA system by vigabatrin, a GABA-transaminase inhibitor. Int J Psychophysiol 1986;4:63-80. (Pubitemid 16067449)
14. Hoke JF, Yuh L, Antony KK, Okerholm RA, Elberfeld JM, Sussman NM. Pharmacokinetics of vigabatrin following single and multiple doses in normal volunteers. J Clin Pharmacol 1993;33:458-62. (Pubitemid 23169242)
15. Haegele KD, Schechter PJ. Kinetics of the enantiomers of vigabatrin after an oral dose of the racemate or the active S-enantiomer. Clin Pharmacol Ther 1986;40:581-6. (Pubitemid 17185095)
16. Frisk-Holmberg M, Kerth P, Meyer P. Effect of food on the absorption of vigabatrin. Br J Clin Pharmacol 1989;27:S23-5.
17. Vauzelle-Kervroedan F, Rey E, Pons G, et al. Pharmacokinetics of individual enantiomers of vigabatrin in neonates with uncontrolled seizures. Br J Clin Pharmacol 1996;42:779-81. (Pubitemid 26417622)
18. Rey E, Pons G, Richard MO, et al. Pharmacokinetics of the individual enantiomers of vigabatrin (γ-vinyl GABA) in epileptic children. Br J Clin Pharmacol 1990;30:253-7. (Pubitemid 20237898)
19. Grove J, Schechter PJ, Tell G, et al. Increased γ-aminobutyric acid (GABA), homocarnosine and β-alanine in cerebrospinal fluid of patients treated with γ-vinyl GABA (4-amino-hex-5-enoic acid). Life Sci 1981;28:2431-9.
20. Schechter PJ, Hanke NFJ, Grove J, Huebert N, Sjoerdsma A. Biochemical and clinical effects of γ-vinyl GABA in patients with epilepsy. Neurology 1984;34:182-6. (Pubitemid 14185361)
21. Riekkinen PJ, Ylinen A, Halonen T, Sivenius J, Pitkanen A. Cerebrospinal fluid GABA and seizure control with vigabatrin. Br J Clin Phamacol 1989;27:S87-94.
22. Pitkanen A, Matilainen R, Ruutiainen T, Riekkinen P. Levels of total γ-aminobutyric acid (GABA), free GABA and homocarnosine in cerebrospinal fluid of epileptic patients before and during γ-vinyl-GABA (vigabatrin) treatment. J Neurol Sci 1988;88:83-93. (Pubitemid 19016585)
23. Ben-Menachem E, Persson Li, Schechter PJ, et al. Effects of single doses of vigabatrin on CSF concentrations of GABA, homocarnosine, homovanillic acid and 5-hydroxyindoleacetic acid in patients with complex partial epilepsy. Epilepsy Res 1988;2:96-101. (Pubitemid 18063162)
24. Grant SM, Heel RC. Vigabatrin: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in epilepsy and disorders of motor control. Drugs 1991;41:889-926. (Pubitemid 21920756)
25. Schechter PJ. Clinical pharmacology of vigabatrin. Br J Clin Pharmacol 1989;27:S19-22.
26. Yu DK, Hutcheson SJ, Wei G, Bhargava VO, Weir SJ. A comparison of population and standard two-stage pharmacokinetic analyses of vigabatrin data. Biopharm Drug Dispos 1994;15:473-84. (Pubitemid 24255661)
27. Ifergane G, Masalha R, Zigulinski R, Merkin L, Wirguin I, Herishanu YO. Acute encephalopathy associated with vigabatrin monotherapy in patients with mild renal failure. Neurology 1998;51:314-15. (Pubitemid 28345414)
28. Rey E, Pons G, Olive G. Vigabatrin: clinical pharmacokinetics. Clin Pharmacokinet 1992;23:267-78.
29. Jung MJ, Lippert B, Metcalf BW, Bohlen P, Schechter PJ. γ-vinyl GABA (4-amino-hex-5-enoic acid), a new selective irreversible inhibitor of GABA-T: effects on brain GABA metabolism in mice. J Neurochem 1977;29:797-802.
30. Schechter PJ, Trainer Y, Jung MJ, Bohlen P. Audiogenic seizure protection by elevated brain GABA concentration in mice: effects of γ-acetylenic GABA and γ-vinyl GABA, two irreversible GABA-T inhibitors. Eur J Pharmacol 1977;45:319-28. (Pubitemid 8172292)
31. Tong X, Ratnaraj N, Patsalos PN. Vigabatrin extracellular pharmacokinetics and concurrent γ-aminobutyric acid neurotransmitter effects in rat frontal cortex and hippocampus using microdialysis. Epilepsia 2009;50:174-83.
32. Gibson JP, Yarrington JT, Loudy DE, Gerbig CG, Hurst GH, Newberne JW. Chronic toxicity studies with vigabatrin, a GABA-transaminase inhibitor. Toxicol Pathol 1990;18:225-38. (Pubitemid 20294457)
33. Kalviainen R, Halonen T, Pitkanen A, Riekkinen PJ. Amino acid levels in the cerebrospinal fluid of newly diagnosed epileptic patients: effect of vigabatrin and carbamazepine monotherapies. J Neurochem 1993;60:1244-50. (Pubitemid 23088297)
34. Ben-Menachem E, Persson LI, Mumford J, Haegele KD, Huebert N. Effect of long-term vigabatrin therapy on selected neurotransmitter concentrations in cerebrospinal fluid. J Child Neurol 1991;6(suppl):2S11-16.
35. Rothman DL, Petroff OAC, Behar KL, Mattson RH. Localized 1H NMR measurements of γ-aminobutyric acid in human brain in vivo. Proc Natl Acad Sci USA 1993;90:5662-6. (Pubitemid 23176221)
36. 1H spectroscopic measurements of γ-aminobutyric acid, glutamate, and glutamine in human brain. Epilepsia 1995;36:457-64.
37. Petroff OAC, Rothman DL, Behar KL, Mattson RH. Human brain GABA levels rise after initiation of vigabatrin therapy but fail to rise further with increasing dose. Neurology 1996;46:1459-63. (Pubitemid 26159316)
38. Petroff OAC, Behar KL, Mattson RH, Rothman DL. Human brain γ-aminobutyric acid levels and seizure control following initiation of vigabatrin therapy. J Neurochemistry 1996;67:2399-404. (Pubitemid 26392510)
39. Petroff OAC, Rothman DL, Behar KL, Collins BA, Mattson RH. Human brain GABA levels rise rapidly after initiation of vigabatrin therapy. Neurology 1996;47:1567-71. (Pubitemid 26422556)
40. 123I]iomazenil SPECT and GABA MRS. Epilepsia 1999;40:1433-8.
41. Novotny EJ, Hyder F, Shevell M, Rothman DL. GABA changes with vigabatrin in the developing human brain. Epilepsia 1999;40:462-6. (Pubitemid 29164858)
42. A-receptor binding in young children with epilepsy. Epilepsia 2001;42:1320-6.
43. Bolton JB, Rimmer E, Williams J, Richens A. The effect of vigabatrin on brain and platelet GABA-transaminase activities. Br J Clin Pharmacol 1989;27:35S-42.
44. Gram L, Lyon BB, Dam M. γ-Vinyl-GABA: a single-blind trial in patients with epilepsy. Acta Neurol Scand 1983;68:34-9. (Pubitemid 13029064)
45. Browne TR, Mattson MD, Penry JK, et al. Vigabatrin for refractory complex partial seizures: multicenter single-blind study with long-term follow-up. Neurology 1987;37:184-9. (Pubitemid 17015488)
46. Gram L, Klosterskov P, Dam M. γ-Vinyl GABA: a double-blind placebo-controlled trial in partial epilepsy. Ann Neurol 1985;17:262-6. (Pubitemid 15136600)
47. Cocito L, Maffini M, Perfumo P, Roncallo F, Loeb C. Vigabatrin in complex partial seizures: a long-term study. Epilespy Res 1989;3:160-6. (Pubitemid 19071185)
48. Arteaga R, Herranz JL, Valdizán EM, Armijo JA. γ-Vinyl GABA (vigabatrin): relationship between dosage, plasma concentrations, platelet GABA-transaminase inhibition, and seizure reduction in epileptic children. Epilepsia 1992;33:923-31.
49. Hancock E, Osborne JP. Vigabatrin in the treatment of infantile spasms in tuberous sclerosis: literature review. J Child Neurol 1999;14:71-4. (Pubitemid 29146614)
50. Mackay MT, Weiss SK, Adams-Webber T, et al. Practice parameter: medical treatment of infantile spasms. Report of the American Academy of Neurology and the Child Neurology Society. Neurology 2004;62;1668-81.
51. Chiron C, Dumas C, Jambaqué I, Mumford J, Dulac O. Randomized trial comparing vigabatrin and hydrocortisone in infantile spasms due to tuberous sclerosis. Epilepsy Res 1997;26:389-95. (Pubitemid 27117815)
52. Vigevano F, Cilio MR. Vigabatrin versus ACTH as first-line treatment for infantile spasms: a randomized prospective study. Epilepsia 1997;38:1270-4. (Pubitemid 28007515)
53. Appleton RE, Peters ACB, Mumford JP, Shaw DE. Randomised, placebo-controlled study of vigabatrin as first-line treatment of infantile spasms. Epilepsia 1999;40:1627-33. (Pubitemid 29518094)
54. Elterman RD, Shields WD, Bittman RM, Torri SA, Sagar SM, Collins SD. Vigabatrin for the treatment of infantile spasms: final report of a randomized trial. J Child Neurol 2010;25:1340-7.
55. Askalan R, Mackay M, Brian J, et al. Prospective preliminary analysis of the development of autism and epilepsy in children with infantile spasms. J Child Neurol 2003;18:165-70. (Pubitemid 36527422)
56. Lux AL, Edwards SW, Hancock E, et al. The United Kingdom infantile spasms study comparing vigabatrin with prednisolone or tetracoside at 14 days: a multicentre, randomised controlled trial. Lancet 2004;364:1773-8. (Pubitemid 39488062)
57. Lux AL, Edwards SW, Hancock E, et al. The United Kingdom infantile spasms study (UKISS) comparing hormone treatment with vigabatrin on developmental and epilepsy outcomes to age 14 months: a multicentre randomised trial. Lancet Neurol 2005;4:712-17. (Pubitemid 41457286)
58. Darke K, Edwards SW, Hancock E, et al. Developmental and epilepsy outcomes at age 4 years in the UKISS trial comparing hormonal treatments to vigabatrin for infantile spasms: a multicentre randomised trial. Arch Dis Child 2010;95:382-6.
59. Jambaqué I, Chiron C, Dumas C, Mumford J, Dulac O. Mental and behavioral outcome of infantile epilepsy treated by vigabatrin in tuberous sclerosis patients. Epilepsy Res 2000;38:151-60.
60. Cohen-Sadan S, Kramer U, Ben-Zeev B, et al. Multicenter long-term follow-up of children with idiopathic West syndrome: ACTH versus vigabatrin. Eur J Neurol 2009;16:482-7.
61. Camposano SE, Major P, Halpern E, Thiele EA. Vigabatrin in the treatment of childhood epilepsy: a retrospective chart review of efficacy and safety profile. Epilepsia 2008;49:1186-91. (Pubitemid 351991397)
62. Karvelas G, Lorti A, Scantlebury MH, Duy PT, Cossette P, Carmant L. A retrospective study on aetiology based outcome of infantile spasms. Seizure 2009;18:197-201.
63. U.S. Food and Drug Administration. Drugs @ FDA. FDAapproved drug products. Center for Drug Evaluation and Research. Summary review. Application number: 20-427. Available from www.accessdata.fda.gov/drugsatfda-docs/nda/2009/ 020427s000-SumR.pdf. Accessed May 1, 2010.
64. Cohen JA, Fisher RS, Brigell MG, Peyster RG, Sze G. The potential for vigabatrin-induced intramyelinic edema in humans. Epilepsia 2000;41:148-57. (Pubitemid 30097059)
65. Pearl PL, Vezina LG, Saneto RP, et al. Cerebral MRI abnormalities associated with vigabatrin therapy. Epilepsia 2009;50:184-94.
66. Nabbout R. A risk-benefit assessment of treatments for infantile spasms. Drug Saf 2001;24;813-28. (Pubitemid 32937973)
67. Eke T, Talbot JF, Lawden MC. Severe persistent visual field constriction associated with vigabatrin Br Med J 1997;31:180-1.
68. Willmore LJ, Abelson MB, Ben-Menachem E, Pellock JM, Shields WD. Vigabatrin: 2008 update. Epilepsia 2009;50:163-73.
69. Wheless JW, Ramsay ER, Collins SD. Vigabatrin. Neurotherapeutics 2007;4:163-72.
70. Kjellstromöm U, Bruun A, Ghosh F, Andréasson S, Ponjavic V. Dose-related changes in retinal function and PKC-alpha expression in rabbits on vigabatrin medications. Graefes Arch Clin Exp Ophthalmol 2009;247:1057-67.
71. Lawthorn C, Smith PEM, Wild JM. Nasal retinal nerve fiber layer attenuation: a biomarker for vigabatrin toxicity. Ophthalmology 2009;116:565-71.
72. Franciotta D, Kwan P, Perucca E. Genetic basis for idiosyncratic reactions to antiepileptic drugs. Curr Opin Neurol 2009;22:144-9.
73. Conway M, Cubbidge RP, Hosking SL. Visual field severity indices demonstrate dose-dependent visual loss from vigabatrin therapy. Epilepsia 2008;49:108-16.
74. Hwang H, Kim KJ. New antiepileptic drugs in pediatric epilepsy. Brain Dev 2008;30:549-55.
75. National Institute of Neurological Disorders and Stroke. The effect of vigabatrin on cerebral blood flow and glucose metabolism. ClinicalTrials.gov. Bethesda, MD: National Library of Medicine. Available from http:// clinicaltrials.gov/ct2/show/NCT00001489. Accessed May 1, 2010.
76. All India Institute of Medical Sciences, New Delhi. Efficacy and tolerability of the modified Atkins diet in patients with infantile spasms: a pilot study. ClinicalTrials.gov. Bethesda, MD: National Library of Medicine. Available from http://clinicaltrials.gov/ct2/show/NCT01006811. Accessed May 1, 2010.
77. Oslo University Hospital. Comparing ketogenic diet with the most appropriate antiepileptic drug: a randomized study of children with mental retardation and drug resistant epilepsy. ClinicalTrials.gov. Bethesda, MD: National Library of Medicine. Available from http://clinicaltrials.gov/ct2/show/ NCT00552526. Accessed May 1, 2010.
78. University of Bath, United Kingdom. The international collaborative infantile spasms study (ICISS). Available from www.bath.ac.uk/health/research/ iciss/index.php. Accessed May 1, 2010.
79. U.S. Food and Drug Administration. Approved risk evaluation and mitigation strategies (REMS). Available from www.fda.gov/Drugs/DrugSafety/ PostmarketDrugSafetyInformationforPatientsandProviders/ucm111350.htm. Accessed May 1, 2010.
80. Lundbeck Inc. Support, help, and resources for epilespy (SHARE) program. Available from www.lundbeckshare.com/pg512-important-steps.aspx. Accessed May 1, 2010.
81. National Institute for Health and Clinical Excellence. The diagnosis and management of the epilepsies in adults and children in primary and secondary care, October 2004. Available from www.nice.org.uk/nicemedia/pdf/ CG20fullguideline.pdf. Accessed February 20, 2010.
82. Scottish and Intercollegiate Guidelines Network. Diagnosis and management of epilepsies in children and young people: a national clinical guideline, March 2005. Available from www.sign.ac.uk/pdf/sign81.pdf. Accessed February 20, 2010.
83. Tsuji T, Okumura A, Ozawa H, Ito M, Watanabe K. Current treatment of West syndrome in Japan. J Child Neurol 2007;22:560-4. (Pubitemid 46951499)
84. Wheless JW, Clarke DF, Arzimanoglou A, Carpenter D. Treatment of pediatric epilepsy: European expert opinion, 2007. Epileptic Disord 2007;9:353-412. (Pubitemid 351147653)
85. Hancock EC, Osborne JP, Edwards SW. Treatment of infantile spasms. Cochrane Database Syst Rev 2008;(4):CD001770.